The clinical value of determination of natriuretic peptides in acute coronary syndrome


Cite item

Full Text

Abstract

The production and release of natriuretic peptides (NPs) into the bloodstream are stimulated by increased left ventricular wall tension during volume overload. In ischemia, NPs are secreted by myocardial cells in response to stress or overload, particularly in the development of myocardial systolic dysfunction. The review details the time course of changes in amino acid N-terminal proBNP in acute coronary syndrome (ACS) with and without ST-segment elevation and discusses the role of the index in defining the tactics of treatment and prognosis in patients with ACS.

References

  1. Sudoh T., Kangawa K., Minamino N. et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
  2. Mykoyama M., Nakao K., Hosada K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J. Clin. Invest. 1991; 87: 1402-1412.
  3. Верткин А. Л., Сапрыгин Д. Б., Мошина В. А. Мозговой натрийуретический пептид при остром коронарном синдроме без подъема сегмента ST. Лечащий врач 2006; 6: 14- 16.
  4. McDowell G., Shaw C., Buchanan K. et al. The natriuretic peptide family. Eur. J. Clin. Invest. 1995; 25: 291-298.
  5. Tamura N., Ogawa Y., Yasoda A. et al. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J. Mol. Cell. Cardiol. 1996; 28: 481-509.
  6. Richards A., Nicholls M., Yandle T. et al. Plasma N-terminal Pro-brain natriuretic peptide and adrenomedullin. Circulation 1998; 97: 1921-1929.
  7. Сапрыгин Д. В., Мошина В. А. Клиническое значение определения мозгового натрийуретического пептида (аминотерминального фрагмента) - NT-proBNP, при кардиоваскулярной патологии. Лаб. мед. 2006; 8: 1-8.
  8. Yandle T. Biochemistry of natriuretic peptides. J. Intern. Med. 1994; 235: 561-576.
  9. Miller W., Hartman K., Buritt M. et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007; 116: 249- 257.
  10. Jourdain P., Jondeau G., Funck F. et al. Plasma brain-natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP multicenter study. J. Am. Coll. Cardiol. 2007; 49(16): 1733-1739.
  11. Mo V., De Lemos J. Individualizing therapy in acute coronary syndromes: Using a multiple biomarker approach for diagnosis, risk stratification, and guidance therapy. Curr. Cardiol. Rep. 2004: 6(4): 273-278.
  12. Hama N., Itoh H., Shirakami G. et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92: 1558- 1564.
  13. Riezebos R., Ronner E., Tijssen J. et al. NT-proBNP serum levels reflect severity and extent of ischemia in patients admitted with non-ST-elevation acute coronary syndrome. Acute Cardiac Care 2006; 8: 51-57.
  14. Sahinarslan A., Cengel A., Okyay K. et al. B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease. Coronary Artery Dis. 2005; 16(4): 225-229.
  15. Tataeshi J., Masutami M., Ohyanagi M. et al. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin. Cardiol. 2000; 23: 776-780.
  16. McClure S., Gall S., Schehter C. et al. Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration is stable coronary artery disease. J. Am. Coll. Cardiol. 2007; 49(25): 2394-2397.
  17. Bonaca M. P., Wiviott S. D., Sabatine M. S. et al. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal proB-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from JUMBO-TIMI 26 trial). Am. J. Cardiol. 2007; 99(3): 344-348.
  18. Marumoto K., Hamada H., Hiwada K. et al. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin. Sci. 1995; 88: 551-556.
  19. Yeo K., Siegel A., Wong K. et al. Detection of exercise-induced ischemia by measurement of NT-proBNP. Clin. Chem. 2003; 49(6): suppl. A67.
  20. Bayes-Genis A., Januzzi J. NT-proBNP as a biomarker in cardiovascular diseases. Boston: Thomson Reuters; 2008.
  21. Lindahl B., Lindback J., Jemberg T. et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment acute coronary syndromes: a Fragmin and fast Revascularization during IN Stability in Coronary artery disease (FRISC)-II substudy. J. Am. Coll. Cardiol. 2005; 45: 533-541.
  22. James S., Lindahl B., Siegbahn A. et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275-281.
  23. James S., Lindback J., Tilly J. et al. Troponin T and N-Terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes. A GUSTO-IV substudy. J. Am. Coll. Cardiol. 2006; 48: 1146-1154.
  24. Weber M., Bazzino O., Navarro Estrada J. L. et al. N-Terminal pro-B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J. Am. Coll. Cardiol. 2008; 51(12): 1188-1195.
  25. Morita E., Yasue H., Yoshimura M. et al. Increased plasma levels of brain natriuretic peptide concentrations in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
  26. Talwar S., Squire I., Downie P. F. et al. Profile of plasma N-terminal pro-brain natrieretic peptide in patients with acute myocardial infarction. Eur. Heart J. 2000; 21: 1514-1521.
  27. Шрейдер Е. В., Шахнович Р. М., Казначеева Е. И. и др. Сравнительная динамика маркеров воспаления и NT-proBNP при различных вариантах лечения больных с острым коронарным синдромом. Кардиология 2008; 8: 20- 27.
  28. Heeschen C., Hamm C., Mitrivic V. et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110: 3206-3212.
  29. Talwar S., Squire I., Downie P. F. et al. Profile of plasma N-terminal pro-brain natrieretic peptide following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur. Heart J. 2000; 21: 1514-1521.
  30. Seino Y., Ogawa A., Yamashita T. et al. Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Fail. 2004; 6: 295-300.
  31. Bassan R., Potsch A., Maisel A. et al. B-type natrieretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur. Heart J. 2005; 26: 234-240.
  32. Kwan G., Isakson S., Beede J. et al. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J. Am. Coll. Cardiol. 2007; 49: 1186-1192.
  33. Mitchell A., Garvey J., Kline J. Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad. Emerg. Med. 2006; 13: 803-806.
  34. de Lemos J., Morrow D., Bentley J. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 2001; 345: 1014-1021.
  35. Galvani M., Ottani F., Oltrona L. et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes N-terminal pro-brain natriuretic peptide on admission has prognostic value. Circulation 2004; 110: 128-134.
  36. Omland T., Persson A., Ng L. et al. N-terminal pro-brain natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-2918.
  37. Sabatine M., Morrow D., de Lemos J. et al. Multimarker approach to risk stratification in Non-ST elevation acute coronary syndromes. Circulation 2002; 105: 1760-1763.
  38. Crilley J., Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart 2001; 86: 638-642.
  39. Bjorklund E., Jernberg T., Johanson P. et al. Admission NT-proBNP and its interaction with admission troponin T and ST-segment resolution for early risk stratification in ST-elevation myocardial infarction. Heart 2005.
  40. Inoue T., Sakuma M., Yaguchi I. et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am. Heart J. 2002; 143: 790-796.
  41. Richards A., Nicholls M., Yandex T. et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999; 81: 114-120.
  42. Richards A., Nicholls M., Espiner E. et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-2792.
  43. Jernberg T., Stridsberg M., Venge P. et al. N-terminal pro-brain natriuretic peptide on admission for early risk stratification of patients with chest pain an no ST-segment elevation. J. Am. Coll. Cardiol. 2002; 40: 437-445.
  44. Morrow D., de Lemos J., Blazing M. et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. J. A. M. A. 2005; 294: 2866-2871.
  45. Morrow D., de Lemos J., Sabatine M. et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/ non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol. 2003; 41: 1264-1272.
  46. Winhausen F., Hirsch A., Sanders G. et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am. Heart J. 2007; 153: 485-492.
  47. Jernberg T., Lindahl B., Siegbahn A. et al. N-terminal pro brain-natriuretic peptide in relation to inflammation, myocardial necrosis and the effect of an invasive strategy in unstable coronary artery disease. J. Am. Coll. Cardiol. 2003; 42(11): 1909-1916.
  48. Richards A., Doughty R., Nicholls M. et al. Plasma N-terminal pro-B-type natriuretic peptide and adrenomedullin prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 2001; 37: 1781- 1787.
  49. Bjorklund E., Jernberg T, Johanson P. et al. Admission NT-proBNP and its interaction with admission troponin T and ST-segment resolution for early risk stratification in ST-elevation myocardial infarction. Heart 2006; 92: 735-740.
  50. Lorgis L., Zeller M., Dentan G. et al. High levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction. Quart. J. Med. 2007; 100: 211-216.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies